Want to see APRE full AI Analyst Report?
APRE Stock Chart & Stats
$0.63
<$0.01(0.16%)
At close: 4:00 PM EDT
$0.63
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$0.55 - $1.85
Previous Close$0.61
Volume18.33K
Average Volume (3M)55.77K
Market Cap
$7.68M
Enterprise Value-$34.54
Total Cash (Recent Filing)$46.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Aug 06, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding12,382,776
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.30Price Target Upside582.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$1.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtAprea's effectively zero debt position materially reduces near-term refinancing and interest-rate exposure, giving the company structural financial flexibility. For a clinical-stage biotech this limits one common failure pathway and preserves optionality while programs advance toward value-driving data.
Extended Cash Runway From FinancingThe oversubscribed $30M placement and $46.5M cash balance extend runway into early 2028, reducing immediate dilution pressure and allowing the company to pursue planned expansions and dose escalation. This funding materially improves the firm's ability to reach mid-stage readouts without urgent refinancing.
Clinical Progress On Lead Asset (APR-1051)Positive signals (partial responses and tolerability) and an explicit plan to expand APR-1051 enrollment de-risk the lead program over the medium term. Successful clinical progression and upcoming ASCO data create durable scientific validation that can support partnerships or later-stage financing.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow (~-$12.2M TTM) means the business cannot self-fund development and needs external capital to sustain operations. Over 2-6 months this structural cash burn maintains dilution risk and constrains long-term strategic options if clinical timelines slip.
Ongoing Losses And Weak Revenue TrajectoryRevenue volatility and persistent net losses reflect a lack of commercial cash flow and confirm a development-stage profile. Without recurring revenue, the firm remains dependent on capital markets; sustained negative EBIT reduces flexibility to invest in multiple programs simultaneously.
Pipeline Execution Uncertainty (ATRN-119 Pause)Pausing the ATRN-119 monotherapy program to explore combination approaches increases development complexity, lengthens timelines, and raises execution risk. This strategic shift can require additional studies, partners, or capital and may delay value realization from that asset.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $1.85 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $7.68M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.212 by -$0.008.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.18.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 12,382,776 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.212. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics. The company’s pipeline has centered on small-molecule drug candidates intended to target tumor biology (historically including programs aimed at p53-related pathways) and other oncology approaches, with activities primarily in research and clinical development rather than commercial product sales.
APRE Stock 12 Month Forecast
Average Price Target
$4.30
▲(582.54% Upside)
Technical Analysis
Ownership Overview
6.50% Insiders
0.86% Mutual Funds
15.36% Other Institutional Investors
77.10% Public Companies and
Individual Investors